πŸ‡ΊπŸ‡Έ FDA
Patent

US 10759759

Prodrugs of kallikrein inhibitors

granted A61PA61P29/00

Quick answer

US patent 10759759 (Prodrugs of kallikrein inhibitors) held by BioCryst Pharmaceuticals, Inc. expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BioCryst Pharmaceuticals, Inc.
Grant date
Tue Sep 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61P, A61P29/00